Background Cataract is a significant cause of preventable blindness in the United Kingdom and worldwide. Prior to the COVID-19 pandemic, cataract surgery was the most commonly performed operation by the National Health Service in the United Kingdom. The aim of this study is to evaluate the safety of elective cataract surgery performed in the United Kingdom in a COVID-19 free hospital during the COVID-19 pandemic. Methods Single centre prospective observational cohort study of consecutive patients undergoing elective cataract surgery in the United Kingdom over a 3 month period from May to August 2020. Electronic medical records were reviewed and patients were contacted at 30 days post-operatively. Data collection included symptoms suggestive of COVID-19 infection, hospital admission, mortality, intra-operative and post-operative surgical complications. Results A total of 649 elective cataract surgeries were performed. Two patients (0.3%) developed worsening dyspnoea during the 30 day post-operative period, but tested negative for COVID-19 infection. Three patients (0.5%) were hospitalised, unrelated to COVID-19 infection, of which one patient (0.2%) passed. Four patients (0.6%) suffered posterior capsular rupture. 601 (93.2%) had no post-operative complications. Conclusion This study demonstrates a safe model for the resumption of elective cataract surgery during the COVID-19 pandemic, providing strict infection control measures are in place.

No abstract

Dimox and the other carbonic anhydrase inhibitors now form a standard adjunct to the treatment of glaucoma throughout the world, and the literature dealing with these substances is very extensive. In spite of the numerous drugs available, search is continuing for the least toxic and also for one requiring less frequent administration.The present study was carried out to evaluate the action of sustainedrelease Diamox Sequel (Lederle ), produced in a 500-mg. capsule containing 125 mg. ordinary acetazolamide and 375 mg. sustained-release acetazolamide, and to compare it with a single dose of ordinary acetazolamide which starts to reduce intra-ocular pressure after 30 to 90 minutes and reaches its maximum in 1 to 5 hours, the duration of action being somewhere between 8 and 12 hours (Leydhecker, 1960). NORMAL EYES (A) Investigation.-The action of a single dose of 500 mg. Diamox Sequel was studied in ten eyes of six patients. This group consisted of patients who were admitted to the eye department and in whom glaucoma was excluded by diurnal ocular tension curves, tonographic studies, visual fields, and a normal appearance of the optic nervehead. Diurnal ocular tension curves were carried out for 48 hours, the intra-ocular pressure being taken first at 6 a.m. (on waking) and then at 3-hrly intervals during the day until 10 p.m. The patient was then given a test dose of 500 mg. Diamox Sequel and the ocular tension curve was continued for the next 24 hours. The changes in intra-ocular pressure were compared with the pressure before the administration of Diamox at the same time of day.(B) Results.-In all the ten normal eyes tested a fall in intra-ocular pressure *

No abstract

Background: This study was designed to evaluate visual, refractive and safety outcomes in eyes after they underwent phacoemulsification and implantation of a preloaded monofocal hydrophobic acrylic intraocular lens.Methods: This was a single center prospective study conducted at Ashford and St Peter’s Hospitals NHS Foundation Trust, United Kingdom. Patients were included if they had cataract extraction with in-the-bag implantation of the EyeCee® One preloaded intraocular lens from August to October 2019. Pre-operative, surgery-related and 2 weeks and 3 months post-operative data was collected. Surgeons at this trust were then asked to complete a feedback form to evaluate their experience of implanting the EyeCee® One. Results: 152 eyes were included in the study. 94 (62%) of these eyes had cataract but no concomitant ocular pathology that could potentially affect visual acuity. Three months post-operatively, 98.7% of all eyes had monocular CDVA ≤ 0.3 logMAR. 100% of the eyes without concomitant ocular pathology achieved this target. The mean CDVA of all eyes in this study improved from 0.43 ± 0.43 logMAR pre-operatively, to 0.05 ± 0.11 logMAR post-operatively (p < 0.05). The mean sphere and spherical equivalent values showed significant improvements (p <0.05) and (p < 0.05). There were no intraoperative complications and 1.3% of patients reported complications 2 weeks post-operatively. All of the participating surgeons said they would use the EyeCee® One again with 64% providing an overall rating of ‘excellent’ for their experience of implanting this intraocular lens. Conclusions: This study indicates excellent post-operative visual acuity and refractive outcomes in eyes after EyeCee® One implantation. This is accompanied with very little risk of intraoperative and post-operative complications.